– USA, CA – DayTwo, the leader in precision nutrition with the world’s most advanced proprietary microbiome science, today announced the appointment of David Henderson, a former founding executive member of Oscar Health, as CEO.
“I’m thrilled to be joining a unique and innovative company that is helping people live healthier lives and manage their chronic conditions,” said CEO, David Henderson. “The company employs the most advanced microbiome analysis in the world, resulting in groundbreaking clinical discoveries and life-saving disease interventions. With the world’s largest and richest proprietary gut microbiome dataset, DayTwo has tremendous opportunities to apply its science and IP to improve outcomes for other diseases in addition to diabetes, prediabetes, and obesity. I look forward to building on the incredible success of the company and working closely with our innovative clients and partners.”
DayTwo also announced the appointment of John Watts, Jr., CEO of Paradigm, to its board of directors.
“Dave has an outstanding track record of dramatically scaling digital healthcare companies who then become innovators and disruptors,” said Board Chairman, Yair Briman. “We are extremely excited to have Dave’s leadership and talents, to further accelerate DayTwo’s momentum, and continue our extremely fast-paced growth trajectory.”
The company also announced $37 million in new funding led by Cathay Innovation and aMoon, bringing the total fundraise to $85 million. The funds will be used to accelerate its expansion of chronic disease solutions for employers, health plans, and health systems. The financing will support the growing demand for DayTwo’s virtual care solution for metabolic diseases, including diabetes, prediabetes, and obesity. DayTwo’s proven solutions drive significant positive health outcomes for the more than 122 million adults in the U.S. with diabetes and prediabetes.
“Given the staggering crisis related to metabolic disease, DayTwo’s unique and extensible, science-based solution is creating enormous value by solving healthcare and cost challenges, in ways never before imagined. At Cathay Innovation, we leverage our global platform to back and scale technologies in critical fields such as digital health where companies like DayTwo have the potential to positively impact millions of lives. Their program represents the future of disease care, nutrition, and beyond,” said Jacky Abitbol, Managing Partner, Cathay Innovation.
“We are proud of our long-term partnership with DayTwo since its founding. The company has made huge strides and is driving substantial value and meaningful clinical results with employers, health plans, and health systems. We are excited to be a part of this next rapid-growth stage of DayTwo’s commercial success,” said Dr. Yair Schindel, Co-Founder & Managing Partner, aMoon.
About DayTwo
DayTwo, the leader in precision nutrition with the world’s most advanced proprietary microbiome science, offers a sustainable path to remission for metabolic diseases (diabetes, prediabetes, and clinical obesity). Metabolic disease is the first condition to be addressed by DayTwo’s microbiome discovery platform.
The company’s solution includes gut microbiome profiling, artificial intelligence to predict blood sugar response to foods, and dedicated virtual care. The company’s results set a new national benchmark for diabetes and metabolic disease care — with significant sustained clinical results in reducing A1C, improving Time in Range, and reducing or eliminating prescription medications. DayTwo’s scientific research is cited by the National Institutes of Health as a foundational element in its 10 years, $150 million strategic plan for precision nutrition.
For more information: https://www.daytwo.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
